- Home
- UNCY vs ALEC Comparison
UNCY vs ALEC Comparison
Compare UNCY & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UNCY | ALEC |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.4M | 133.2M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | UNCY | ALEC |
|---|---|---|
| Price | $6.01 | $1.76 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 7 |
| Target Price | ★ $44.50 | $3.33 |
| AVG Volume (30 Days) | 351.4K | ★ 1.4M |
| Earning Date | 11-12-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $69,048,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $155.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.26 |
| 52 Week Low | $3.71 | $0.87 |
| 52 Week High | $11.00 | $3.40 |
Technical Indicators
Market Signals| Indicator | UNCY | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 54.75 | 67.61 |
| Support Level | $5.36 | $1.50 |
| Resistance Level | $5.95 | $1.62 |
| Average True Range (ATR) | 0.34 | 0.09 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 72.63 | 90.70 |
Price Performance
Historical ComparisonAbout UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.